USA - engelsk - NLM (National Library of Medicine)

avpak - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - - clopidogrel is indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non–st-segment elevation acs (unstable angina [ua]/ non–st -elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel should be administered in conjunction with aspirin. - clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel is indicated to reduce the rate of mi and stroke. clopidogrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product [see adverse reactions (6.2)] . teratogenic effects risk summary available data from cases reported in published literature and postmarketing surveillance with clopidogrel use in pregnant women have not identified any drug-associated risks for major birth defects or miscarriage [see data]. there are risks to the pregnant woman and fetus associated with myocardial infarction and stroke [see clinical considerations] . no evidence of fetotoxicity was observed when clopidogrel was administered to pregnant rats and rabbits during organogenesis at doses corresponding to 65 and 78 times the recommended daily human dose [see data] . the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk myocardial infarction and stroke are medical emergencies. therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of clopidogrel on the fetus. labor or delivery clopidogrel use during labor or delivery will increase the risk of maternal bleeding and hemorrhage. avoid neuraxial blockade during clopidogrel use because of the risk of spinal hematoma. when possible, discontinue clopidogrel 5 to 7 days prior to labor, delivery, or neuraxial blockade. data human data the available data from published case reports over two decades of postmarketing use have not identified an association with clopidogrel use in pregnancy and major birth defects, miscarriage, or adverse fetal outcomes. animal data embryo-fetal developmental toxicology studies were performed in pregnant rats and rabbits with doses up to 500 mg/kg/day and 300 mg/kg/day, respectively, administered during organogenesis. these doses, corresponding to 65 and 78 times the recommended daily human dose, respectively, on a mg/m 2 basis, revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. risk summary there are no data on the presence of clopidogrel in human milk or the effects on milk production. no adverse effects on breastfed infants have been observed with maternal clopidogrel use during lactation in a small number of postmarketing cases. studies in rats have shown that clopidogrel and/or its metabolites are present in the milk. when a drug is present in animal milk, it is likely that the drug will be present in human milk. the developmental and health benefits of breastfeeding should be considered along with mother's clinical need for clopidogrel and any potential adverse effects on the breastfed infant from clopidogrel or from underlying maternal condition. safety and effectiveness in pediatric populations have not been established. a randomized, placebo-controlled trial (clarinet) did not demonstrate a clinical benefit of clopidogrel in neonates and infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt. possible factors contributing to this outcome were the dose of clopidogrel, the concomitant administration of aspirin and the late initiation of therapy following shunt palliation. it cannot be ruled out that a trial with a different design would demonstrate a clinical benefit in this patient population. of the total number of subjects in the caprie and cure controlled clinical studies, approximately 50% of patients treated with clopidogrel were 65 years of age and older, and 15% were 75 years and older. in commit, approximately 58% of the patients treated with clopidogrel were 60 years and older, 26% of whom were 70 years and older. the observed risk of bleeding events with clopidogrel plus aspirin versus placebo plus aspirin by age category is provided in table 1 and table 2 for the cure and commit trials, respectively [see adverse reactions (6.1)] . no dosage adjustment is necessary in elderly patients. experience is limited in patients with severe and moderate renal impairment [see clinical pharmacology (12.2)] . no dosage adjustment is necessary in patients with hepatic impairment [see clinical pharmacology (12.2)] .

Singapore - engelsk - HSA (Health Sciences Authority)

beijing tong ren tang science arts (singapore) co pte. ltd. - capsules

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. ibuprofen tablets are indicated for relief of mild to moderate pain. ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen. ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, an

Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة نهر الاردن للصناعات الدوائية - jordan river pharmaceutical industries - calcium polystyrene sulphonate 93.5 % - 93.5%

USA - engelsk - NLM (National Library of Medicine)

professional complementary health formulas - h3n2 influenza virus 12x, 30x, 60x, 100x - for the temporary relief of chills, cough, minor sore throat, occasional headache, muscle aches, or fatigue.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. ibuprofen tablets are indicated for relief of mild to moderate pain. ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen. ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions and precautions, preexisting asthma). ibuprofen tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

beijing tong ren tang australia pty ltd - lycium barbarum, quantity: 24.4 mg (equivalent: lycium barbarum, qty 24.4 mg); schisandra chinensis, quantity: 3.1 mg (equivalent: schisandra chinensis, qty 3.1 mg); rubus chingii, quantity: 12.2 mg (equivalent: rubus chingii, qty 12.2 mg); cuscuta hygrophilae, quantity: 24.4 mg (equivalent: cuscuta hygrophilae, qty 24.4 mg); plantago asiatica, quantity: 6.1 mg (equivalent: plantago asiatica, qty 6.1 mg) - pill - excipient ingredients: purified honey - traditionally used in chinese medicine to nourish/tonify/warm/boost/invigorate/strengthen kidney-essence/kidney-jing ; traditionally used in chinese medicine to strengthen/enrich/restore kidney jing ; traditionally used in chinese medicine to analgesic/anodyne/relieve pain ; traditionally used in chinese medicine to male tonic ; traditionally used in chinese medicine to maintain/support healthy urine output

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

beijing tong ren tang australia pty ltd - rehmannia glutinosa, quantity: 48 mg (equivalent: rehmannia glutinosa, qty 120 mg); wolfiporia cocos, quantity: 18 mg (equivalent: wolfiporia cocos, qty 45 mg); paeonia suffruticosa, quantity: 18 mg (equivalent: paeonia suffruticosa, qty 45 mg); cornus officinalis, quantity: 24 mg (equivalent: cornus officinalis, qty 60 mg); alisma orientale, quantity: 18 mg (equivalent: alisma orientale, qty 45 mg); dioscorea oppositifolia, quantity: 24 mg (equivalent: dioscorea oppositifolia, qty 60 mg) - pill - excipient ingredients: maize starch - traditionally used in chinese medicine to relieve weariness/tiredness/fatigue/feeling of weakness ; traditionally used in chinese medicine to decrease/reduce/relieve spontaneous sweating ; traditionally used in chinese medicine to relieve dry mouth ; traditionally used in chinese medicine to decrease/reduce/relieve mild dizziness/vertigo ; traditionally used in chinese medicine to decrease/reduce/relieve disturbed/restless sleep

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

beijing tong ren tang australia pty ltd - vitex trifolia, quantity: 2.23 mg (equivalent: vitex trifolia, qty 13 mg); gardenia jasminoides, quantity: 4.46 mg (equivalent: gardenia jasminoides, qty 26 mg); forsythia suspensa, quantity: 9.1 mg (equivalent: forsythia suspensa, qty 53 mg); rheum palmatum, quantity: 35 mg (equivalent: rheum palmatum, qty 35 mg; equivalent: hydroxyanthracene derivatives calculated as rhein, qty 0.59 mg); scutellaria baicalensis, quantity: 6.01 mg (equivalent: scutellaria baicalensis, qty 35 mg); glycyrrhiza uralensis, quantity: 3.09 mg (equivalent: glycyrrhiza uralensis, qty 18 mg); ligusticum striatum, quantity: 3.09 mg (equivalent: ligusticum striatum, qty 18 mg); schizonepeta tenuifolia, quantity: 3.09 mg (equivalent: schizonepeta tenuifolia, qty 18 mg); mentha haplocalyx, quantity: 3.09 mg (equivalent: mentha haplocalyx, qty 18 mg); lonicera japonica, quantity: 9.1 mg (equivalent: lonicera japonica, qty 53 mg); angelica dahurica, quantity: 22 mg (equivalent: angelica dahurica, qty 22 mg); phellodendron amurense, quantity: 6.01 mg (equivalent: phellodendron amurense, qty 35 mg); coptis chinensis, quantity: 35 mg (equivalent: coptis chinensis, qty 35 mg); chrysanthemum sinense, quantity: 6.01 mg (equivalent: chrysanthemum sinense, qty 35 mg); platycodon grandiflorus, quantity: 26 mg (equivalent: platycodon grandiflorus, qty 26 mg); saposhnikovia divaricata, quantity: 2.23 mg (equivalent: saposhnikovia divaricata, qty 13 mg); inula britannica, quantity: 4.46 mg (equivalent: inula britannica, qty 26 mg); gall stone, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium sulfate dihydrate; magnesium stearate; dl-borneol; maize starch - traditionally used in chinese medicine to decrease/reduce/relieve gum soreness/pain/discomfort ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of mild mouth ulcers ; traditionally used in chinese medicine to decrease/reduce/relieve constipation ; traditionally used in chinese medicine to relieve symptoms of sore throat/pharyngitis ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of facial cold sores

Singapore - engelsk - HSA (Health Sciences Authority)

myhealth sentinel pte. ltd. - general hospital - beijing choice choicemmed fingertip pulse oximeter is intended for spot checking in measuring and displaying functional arterial oxygen saturation (spo2) and pulse rate. it is intended for adult and pediatric users for home healthcare.